Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen.

Piron, Bénédicte; Bastien, Mathilde; Antier, C.; Dalla-Torre, Romain; Jamet, Bastien; Gastinne, Thomas; Dubruille, Viviane; Moreau, Philippe; Martin, Jérôme C.; Bénichou, Antoine; Touzeau, Cyrille; Tessoulin, Benoît

doi:10.3324/haematol.2023.282919

Search citation statements

Order By: Relevance

Paper Sections

Select...

Bispecific Antibodies Targeting T Cell Costimulatory Receptors1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BiTE therapies do carry certain pitfalls, including a short half-life that requires frequent dosing, the risk of cytokine release syndrome that often results in patient hospitalization during cycle 1, and the lack of durable responses due to the development of resistance [ 91 , 92 , 93 ]. CC-1 was one of the early anti-PSMA × CD3 BiTEs in clinical development.…”

Section: Bispecific Antibodies Targeting T Cell Costimulatory Receptorsmentioning

confidence: 99%

Emerging Immunotherapy Approaches for Treating Prostate Cancer

Meng,

Yang,

Mortazavi

et al. 2023

IJMS

View full text Add to dashboard Cite

Immunotherapy has emerged as an important approach for cancer treatment, but its clinical efficacy has been limited in prostate cancer compared to other malignancies. This review summarizes key immunotherapy strategies under evaluation for prostate cancer, including immune checkpoint inhibitors, bispecific T cell-engaging antibodies, chimeric antigen receptor (CAR) T cells, therapeutic vaccines, and cytokines. For each modality, the rationale stemming from preclinical studies is discussed along with outcomes from completed clinical trials and strategies to improve clinical efficacy that are being tested in ongoing clinical trials. Imperative endeavors include biomarker discovery for patient selection, deciphering resistance mechanisms, refining cellular therapies such as CAR T cells, and early-stage intervention were reviewed. These ongoing efforts instill optimism that immunotherapy may eventually deliver significant clinical benefits and expand treatment options for patients with advanced prostate cancer.

show abstract

Section: Bispecific Antibodies Targeting T Cell Costimulatory Receptorsmentioning

confidence: 99%